{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:41:13Z","timestamp":1778233273823,"version":"3.51.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Adjuvant nivolumab prolonged disease-free survival compared with placebo in patients at high risk of recurrence following radical cystectomy or radical nephroureterectomy in the CheckMate 274 trial. However, the ideal eligibility criteria for adjuvant therapy in real-world clinical practice remain controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed clinical data of 409 patients who underwent radical cystectomy (n\u00a0=\u00a0252) or radical nephroureterectomy (n\u00a0=\u00a0157) and validated the risk of recurrence based on the classification used in the CheckMate 274 trial. We also investigated the impact of perioperative chemotherapy, lymph node dissection and pathological factors on prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median follow-up time was 37.5 and 32.1\u00a0months in bladder cancer and upper tract urothelial carcinoma, respectively. Among the high-risk patients based on CheckMate 274 trial, disease-free survival was considerably shorter for bladder cancer and upper tract urothelial carcinoma patients than for low-risk patients (hazard ratios: 4.132 and 7.101, respectively). The prevalence of adjuvant chemotherapy in high-risk patients was low (24 and 38% for bladder cancer and upper tract urothelial carcinoma, respectively). The extent of lymph node dissection in bladder cancer and presence of lymph node dissection in upper tract urothelial carcinoma did not affect prognosis. Cox proportional multivariate analysis revealed CheckMate 274-high-risk as a poor prognostic factor in bladder cancer and upper tract urothelial carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study validated the risk classification for recurrence following radical cystectomy and radical nephroureterectomy using the CheckMate 274 criteria in real-world practice. Further research would help assess the degree of benefit obtained from adjuvant nivolumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad152","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:49:59Z","timestamp":1700077799000},"page":"182-191","source":"Crossref","is-referenced-by-count":6,"title":["Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9121-6461","authenticated-orcid":false,"given":"Taisuke","family":"Matsue","sequence":"first","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kato","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Masuda","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-9729","authenticated-orcid":false,"given":"Shoma","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Takeyama","sequence":"additional","affiliation":[{"name":"Ishikiri Seiki Hospital Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Yukimatsu","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiyo","family":"Otoshi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Kuratsukuri","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Uchida","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka Metropolitan University Department of Urology, , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"2024020717392284800_ref1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.urolonc.2008.10.022","article-title":"Optimal timing of radical cystectomy for patients with T1 bladder cancer","volume":"27","author":"Bochner","year":"2009","journal-title":"Urol Oncol"},{"key":"2024020717392284800_ref2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2024020717392284800_ref3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref4","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.5489\/cuaj.1203","article-title":"Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy","volume":"3","author":"Svatek","year":"2009","journal-title":"Can Urol Assoc"},{"key":"2024020717392284800_ref5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"2024020717392284800_ref6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024020717392284800_ref7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024020717392284800_ref8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"2024020717392284800_ref10","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"2024020717392284800_ref11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref12","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"key":"2024020717392284800_ref13","first-page":"1535","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer JAMA","volume":"4","author":"Peyton","year":"2018","journal-title":"Oncologia"},{"key":"2024020717392284800_ref14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000089993","article-title":"Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen","volume":"69","author":"Adamo","year":"2005","journal-title":"Oncology"},{"key":"2024020717392284800_ref15","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"2024020717392284800_ref16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10147-016-1029-2","article-title":"The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy","volume":"22","author":"Murasawa","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2024020717392284800_ref17","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"2024020717392284800_ref18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"2024020717392284800_ref19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2014.12.008","article-title":"Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy","volume":"67","author":"Yuh","year":"2015","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1742-1241.2011.02888.x","article-title":"A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy","volume":"66","author":"Khan","year":"2012","journal-title":"Int J Clin Pract"},{"key":"2024020717392284800_ref21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.eururo.2014.05.031","article-title":"The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review","volume":"66","author":"Bruins","year":"2014","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201dfor medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2024020717392284800_ref23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jjco\/hyac155","article-title":"Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial","volume":"53","author":"Tomita","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2024020717392284800_ref24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/bco2.117","article-title":"Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer","volume":"3","author":"Miura","year":"2022","journal-title":"BJUI Compass"},{"key":"2024020717392284800_ref25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/SPC.0000000000000505","article-title":"Management of cisplatin-associated toxicities in bladder cancer patients","volume":"14","author":"Desilets","year":"2020","journal-title":"Curr Opin Support Palliat Care"},{"key":"2024020717392284800_ref26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jjco\/hyab210","article-title":"Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer","volume":"52","author":"Omura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024020717392284800_ref27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.eururo.2012.09.053","article-title":"Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node\u2013positive urothelial carcinoma","volume":"63","author":"Fritsche","year":"2013","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref28","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cncr.31372","article-title":"Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis","volume":"124","author":"Danzig","year":"2018","journal-title":"Cancer"},{"key":"2024020717392284800_ref29","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2016.34.15_suppl.4503","article-title":"Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: survival results from a prospective, randomized trial (LEA AUO AB 25\/02)","volume":"34","author":"Gschwend","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024020717392284800_ref30","first-page":"1052","article-title":"SWOG S1011: a phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer","volume":"70","author":"Lerner","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024020717392284800_ref31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"2024020717392284800_ref32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s00330-005-0078-0","article-title":"Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract","volume":"16","author":"Fritz","year":"2006","journal-title":"Eur Radiol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/182\/56610645\/hyad152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/182\/56610645\/hyad152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T17:54:58Z","timestamp":1707328498000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/2\/182\/7423023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11,15]]},"published-print":{"date-parts":[[2024,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad152","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,11,15]]}}}